ABOUT LEX

Our History

• January 2023 – LEX Diagnostics announces the appointment of Ed Farrell as its new Chief Executive Officer. Read more.

• January 2022 – LEX receives core patent grant from USPTO.
  The core innovation making 5 minute sample-to-answer possible is secured.

• September 2021 – LEX demonstrates performance of an RT-PCR assay for detection and differentiation of SARS-CoV-2, Influenza A and Influenza B.

• May 2021 – LEX establishes 100k/yr manufacturing line for its consumables.
  Secures supply for development and clinical studies and starts the journey towards high volume manufacturing.

• March 2021 – GenMark Diagnostics invests in LEX with a definitive option agreement.
  Partnership provides important know-how and insight accelerating our development at an important time.

• September 2020 – LEX expands the scientific team and builds new facilities.
  Grows and brings in-house key capabilities including custom reagent development, bioinformatics and the manufacture of medical consumables.

• February 2020 – LEX Diagnostics Ltd founded as an independent company within the TTP Group.
  Following successful technology demonstration TTP Group invests core intellectual property and key staff into a dedicated company with a mission to commercialise an ultrafast point-of-care diagnostic for respiratory viruses. 

• January 2018 – TTP completes development of a low-cost PCR system for consumer genetic advice for DnaNudge .
  TTP delivers first instrument systems enabling detection of SNPs relevant to personalised nutrition advice in a retail setting. In April 2020 DnaNudge received emergency authorisation for a COVID test using this platform.

• 2018 – TTP demonstrates PCR amplification at 2s/cycle in a low-cost format .
  TTP concludes an internal development program demonstrating key hardware innovations that make recent academic work on ultra-fast PCR thermocycling economic at the point-of-care. 

• 2017 – TTP initiates internal development program to optimise PCR hardware for point-of-care applications.
  Realising that mass adoption of molecular diagnostics at the point-of-care needed a step-change improvement, TTP initiates a whole-system analysis to understand where hardware innovation should be focussed to meet the demands of this emerging market.

• 2016 – TTP completes development of the CLIA-waived binx io point-of-care molecular diagnostics instrument for binx health.

• 2010s – TTP emerges as a world class partner in the development of point-of-care healthcare platforms.
  TTP develops a series of successful point-of-care instruments across immunology, histology and diagnostics.

• 2000s – TTP group companies develop a range of innovative tools & instruments and the importance of ease-of-use grows as a market driver.
  Examples include Mosquito liquid handler (now part of SPTLabtech), veterinary diagnostics for IDEXX and a unique portable PCR diagnostic for Foot-and-Mouth disease – which provides our first experience of molecular diagnostics for infectious disease control.

• 1990s – TTP Group focuses on automation in the life sciences.
  Develops and delivers the production line for Amgen’s Epogen & automates fluorescence microscopy with bioMérieux’s SCANRDI. This work laid the foundation for TAP Biosciences (acquired by Sartorius in 2013) and SPT Labtech (acquired by Battery Ventures in 2018). 

Get in Touch

Learn more about our company and the science behind our revolutionary diagnostics platform.